/
logo

Investors

Investors

EpimAb is supported by an international consortium of investors and has raised $25 million in a Series A financing round to advance the Company’s pipeline of novel bispecific antibodies. The investors include Oriza Seed Capital, Decheng Capital, 3E Bioventure Capital and the Trend Investment Group.

In 2017, EpimAb is supported by an international consortium of investors and has raised $25 million in a Series A financing round to advance the Company’s pipeline of novel bispecific antibodies. The investors include Oriza Seed Capital, Decheng Capital, 3E Bioventure Capital and the Trend Investment Group. In 2019 June, EpimAb raised $74 million USD Series B financing round. The financing was co-led by SDIC Fund and Sherpa Healthcare Partners, and also included investments from SCVC, further private investment entities, and the A round investors, bringing the total funding so far to over $100M USD.